Novavax, Inc. (NVAX) was a big mover last session with its shares rising roughly 12% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has gained nearly 25% in the past one-month time frame.
This clinical-stage vaccine company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Novavax currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Another well-ranked biomedical stock is Cambrex Corp. (CBM) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment